Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

Eisai Inc.0 个研究点开始时间: 2011年9月13日最近更新: 2015年1月26日

适应症

试验速览

阶段: 不适用
状态: No Longer Available
发起方: Eisai Inc.

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to provide continued therapy with Denileukin diftitox (ONTAK) to patients who are currently on therapy and who have no other suitable treatment options, where therapy is requested by their physician.

详细描述

The Access Program will be provided as long as appropriate according to the judgment of the provider. If Denileukin diftitox (ONTAK) becomes commercially available without restriction, then the access program will be discontinued.

研究设计

研究类型: Expanded Access

入排标准

性别: All
接受健康志愿者: 否

入选标准

•To receive denileukin diftitox (ONTAK) under this protocol, the patient's physician must request this therapy for the specific patient. Patients may continue treatment with denileukin diftitox if they:
•Are currently on therapy with denileukin diftitox and require ongoing therapy to maintain control of their disease.
•Are willing and able to comply with all aspects of the Access Protocol
•Provide written informed consent to participate

排除标准

•Patients are not eligible for the Access Program with denileukin diftitox if they:
•Are not currently on denileukin diftitox therapy

研究者

发起方

Eisai Inc.

申办方类型

Industry

责任方

Sponsor

相似试验

撤回

2 期

Denileukine Diftitox for Relapsed ALCLAnaplastic Large-Cell Lymphoma

NCT00801918Columbia University

已完成

2 期

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's LymphomaLymphoma, B-Cell

NCT00211276Eisai Inc.50

已完成

不适用

A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)HIV Infections

NCT00002028Bristol-Myers Squibb

终止

1 期

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous TransplantationMultiple Myeloma

NCT01251952Barbara Ann Karmanos Cancer Institute2

已完成

2 期

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian CancerExtraovarian Peritoneal CancerEpithelial Ovarian CancerFallopian Tube Carcinoma

NCT00880360The University of Texas Health Science Center at San Antonio19